Clinical Trial Update: A Study of the Cypher SES to Treat Restenotic Native Coronary Artery Lesions. [Phase 4]

View source ↗

Summary

Phase 4 study of the Cypher SES to treat restenotic native coronary artery lesions in coronary artery disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Cypher SES (Sirolimus-eluting stent)

Snippet

Sponsor: Cordis US Corp. | Conditions: Coronary Artery Disease | Phase 4 | Status: COMPLETED